TrkB Interacted with Cdk5 and p35

<div><p>(A) TrkA, TrkB, and TrkC all contain proline-directed serine/threonine residues in the juxtamembrane region of the receptors (indicated by arrows). Nonetheless, only TrkB and TrkC contain Cdk5 consensus sites S/TPXK/H/R.</p> <p>(B) Cell lysates from HEK293T cells overexpressing Cdk5 and TrkA, TrkB, or TrkC were immunoprecipitated (IP) with Cdk5 antibody and immunoblotted with pan-Trk antibody. TrkA, TrkB, and TrkC were all observed to associate with Cdk5.</p> <p>(C) Cell lysates from HEK293T cells overexpressing p35 and TrkA, TrkB, or TrkC were immunoprecipitated with p35 antibody and immunoblotted with pan-Trk antibody. TrkA, TrkB, and TrkC were all observed to associate with p35.</p> <p>(D) Brain lysate from P7 rat brain was immunoprecipitated with pan-Trk, p35, or Cdk5 antibody and immunoblotted with p35, Cdk5, and TrkB antibodies. Rabbit normal IgG was used as a control. TrkB was observed to associate with both p35 and Cdk5 in P7 rat brain.</p> <p>(E) The membrane fraction of adult brain lysates was incubated with or without Flag-tagged Cdk5. Flag-tagged Cdk5 pulled down TrkB from the membrane fraction of adult brain lysates.</p> <p>(F) Brain lysates from P7 p35^+/+ or p35^−/− mouse brains were immunoprecipitated with p35 and Cdk5 antibodies and immunoblotted with p35, Cdk5, and TrkB antibodies. Rabbit normal IgG served as a control. Association between Cdk5 and TrkB was abolished in p35^−/− brain, indicating that p35 was required for the association between Cdk5 and TrkB.</p></div

Cdk5 Phosphorylated TrkB at Ser478

<div><p>(A) Lysates from COS7 cells overexpressing TrkA, TrkB, and TrkC were immunoprecipitated with pan-Trk antibody and incubated with Cdk5/p25 in an in vitro kinase assay. TrkB and TrkC, but not TrkA, were phosphorylated by Cdk5/p25.</p> <p>(B) GST-TrkB-juxtamembrane fusion protein was incubated with increasing amount of Cdk5/p35 and subjected to an in vitro kinase assay. Histone H1 served as control to verify the activity of the Cdk5 kinase. The TrkB-juxtamembrane region was phosphorylated by Cdk5/p35 in a dose-dependent manner.</p> <p>(C) Purified WT GST-TrkB-juxtamembrane fusion protein and mutants (M1, M2, and DM) were incubated with Cdk5/p25 in an in vitro kinase assay. While WT and M2 were strongly phosphorylated by Cdk5/p25, phosphorylation of M1 and DM were markedly attenuated. Quality of the purified GST and GST-fusion proteins used in the GST pull-down assay was verified by Coomassie blue staining.</p> <p>(D) Characterization of p-Ser TrkB antibody raised against phosphorylated Ser478 of TrkB. TrkB was overexpressed with or without p35/Cdk5 in HEK293T cells. Preincubation of purified p-Ser478 TrkB antibody with blocking peptide completely abolished detection of Ser478 phosphorylation of TrkB.</p> <p>(E) Full-length TrkB WT, M1, M2, and DM were overexpressed with or without Cdk5/p35 in HEK293T cells. In the absence of Cdk5/p35, Ser478-phosphorylated TrkB (p-Ser TrkB) was not detected. Overexpression of Cdk5/p35 resulted in phosphorylation of TrkB WT at Ser478, but phosphorylation at Ser478 was essentially abolished when TrkB M1 and DM were overexpressed. IP, immunoprecipitation.</p></div

BDNF Enhanced Cdk5 Activity

<div><p>(A) Cortical neurons were stimulated with BDNF for different time intervals. Lysates were immunoprecipitated (IP) with p35 antibody and subjected to in vitro kinase assay using histone H1 as substrate. BDNF stimulation for 15 min resulted in a marked increase in Cdk5 activity in cortical neurons. Quantification of the changes in phospho-Histone H1 level following BDNF stimulation was normalized to the value obtained from untreated cultures (time 0) and is shown in the histogram. *, <i>p <</i> 0.05.</p> <p>(B) Addition of Trk inhibitor K252a abolished BDNF-induced increase in Cdk5 activity. Cortical neurons were pretreated with vehicle control (DMSO) or K252a for 30 min before stimulation with BDNF for 15 min. Lysates were immunoprecipitated with p35 antibody and subjected to in vitro kinase assay using histone H1 as substrate. We found that K252a pretreatment markedly reduced the increase in Cdk5 activity triggered by BDNF stimulation, indicating that the induction of Cdk5 activity was dependent on TrkB activation. Quantification of the changes in phospho-Histone H1 level following BDNF stimulation in the presence or absence of K252a treatment was normalized to the value obtained from untreated cultures (time 0) and is shown in the histogram. *, <i>p <</i> 0.05.</p> <p>(C) Cortical neurons were treated with BDNF for 20 min. Lysates were immunoprecipitated with p35 antibody and immunoblotted with TrkB, p35, or Cdk5 antibody. While association between Cdk5 and p35 was not affected by BDNF stimulation, association between p35 and TrkB increased following 20 min of BDNF stimulation.</p> <p>(D) Recombinant TrkB was incubated with GST-Cdk5 in an in vitro kinase assay. TrkB was found to phosphorylate GST-Cdk5 (middle lane).</p> <p>(E) GST-Cdk5 and recombinant TrkB were pretreated with vehicle (DMSO) or K252a for 10 min, subjected to in vitro kinase assay, and immunoblotted with antibodies against phospho-tyrosine (p-Tyr) and the Tyr15 phosphorylated form of Cdk5 (pTyr15 Cdk5). Cdk5 was phosphorylated by TrkB at Tyr15. Addition of K252a abolished phosphorylation of Cdk5 by TrkB, further verifying that Cdk5 was phosphorylated by TrkB.</p></div

Attenuation of Cdk5 Activity Abolished BDNF-Induced Increase in Primary Dendrites in Hippocampal Neurons

<div><p>(A) Hippocampal neurons were stimulated with BDNF for 3 d in the presence or absence of Ros (10 μM). Interestingly, while BDNF treatment markedly enhanced the number of primary dendrites, treatment with Ros abrogated the increase.</p> <p>(B) Hippocampal neurons were transfected with Cdk5 or DN Cdk5. Twenty-four hours after transfection, cells were exposed to BDNF for 3 d. Overexpression of DN Cdk5 abolished the BDNF-induced increase in primary dendrites.</p> <p>(C) Hippocampal neurons were transfected with Cdk5 siRNA or control siRNA. Twenty-four hours after transfection, cells were exposed to BDNF for 3 d. Transfection with Cdk5 siRNA attenuated Cdk5 expression in hippocampal neurons. More importantly, BDNF-induced increase in primary dendrites was abrogated in Cdk5 siRNA–transfected cells.</p> <p>(D) Hippocampal neurons isolated from <i>cdk5</i>^+/+ and <i>cdk5</i>^−/− brains were treated with BDNF for 3 d. BDNF treatment failed to enhance primary dendrites in Cdk5^−/− neurons.</p> <p>(E) Hippocampal neurons were transfected with TrkB WT or TrkB M1. Twenty-four hours after transfection, cells were exposed to BDNF for 3 d. Overexpression of TrkB M1 markedly reduced the BDNF-induced increase in primary dendrites.</p> <p>Scale bar = 10 μm. *, <i>p <</i> 0.05.</p></div

Cdk5-Mediated Phosphorylation of TrkB Affected BDNF-Induced Dendritic Growth through Attenuation of Cdc42 Activity

<div><p>(A) Hippocampal neurons were transfected with the WT or DN form of Rac1, RhoA, or Cdc42. Twenty-four hours after transfection, cells were exposed to BDNF for 3 d. Overexpression of DN Cdc42 markedly reduced BDNF-induced increase in primary dendrites compared to overexpression of WT Cdc42, indicating that Cdc42 may contribute to the BDNF-dependent induction of dendritic growth in hippocampal neurons.</p> <p>(B) Cortical neurons were pretreated with Cdk5 selective inhibitor Ros or vehicle (DMSO) for 30 min prior to treatment with BDNF for different time intervals. Ros pretreatment markedly reduced BDNF-induced increase in Cdc42 activity following 15 and 30 min of BDNF treatment, indicating that Cdk5 activity was involved in BDNF-triggered Cdc42 activation. Quantification of the changes in Cdc42 activity following BDNF stimulation with or without Ros pretreatment was normalized to the value obtained for the DMSO-treated group at time 0 and is shown in the histogram. *, <i>p <</i> 0.05.</p> <p>(C) TrkB WT or TrkB M1 mutant were co-transfected with WT or CA Cdc42 in hippocampal neurons. Twenty-four hours after transfection, cells were exposed to BDNF for 3 d. Overexpression of CA Cdc42 reversed the abrogation of BDNF-induced increase in primary dendrites following overexpression of TrkB M1. *, <i>p <</i> 0.05.</p> <p>(D) Hippocampal neurons isolated from <i>cdk5</i>^+/+ and <i>cdk5</i>^−/− brains were transfected with WT or CA Cdc42. Twenty-four hours after transfection, cells were exposed to BDNF for 3 d. Overexpression of CA Cdc42 rescued the lack of dendritic growth following BDNF treatment in Cdk5^−/− hippocampal neurons. *, <i>p <</i> 0.05.</p></div

Ser478 Phosphorylation of TrkB Required Cdk5 Activity In Vivo

<div><p>(A) BDNF stimulation resulted in an increase in p-Ser478 TrkB (p-Ser TrkB) levels in cortical neurons. Treatment with Cdk5 selective inhibitor Ros (25 μM) inhibited the BDNF-induced increase in p-Ser478 TrkB, although Ros treatment also resulted in a slight increase in basal p-Ser478 TrkB.</p> <p>(B) <i>cdk5</i>^+/+ and <i>cdk5</i>^−/− brain lysates were immunoblotted against TrkB, phospho-TrkB at Ser478, and β-actin as loading control. p-Ser478 TrkB was almost completely absent in <i>cdk5</i>^−/− brain, indicating the importance of Cdk5 in the phosphorylation of TrkB at Ser478 in vivo.</p> <p>(C) Cortical neurons isolated from <i>cdk5</i>^+/+ and <i>cdk5</i>^−/− brain were treated with BDNF for different periods. Interestingly, while BDNF enhanced TrkB Ser478 phosphorylation in <i>cdk5</i>^+/+ cortical neurons, TrkB Ser478 phosphorylation was not detected in <i>cdk5</i>^−/− neurons, nor did BDNF stimulation enhance Ser478 phosphorylation, indicating that BDNF-stimulated increase in TrkB Ser478 phosphorylation requires Cdk5 activity.</p></div

OEOA did not induce cell death in K562 and HEL cells.

<p>K562 (A & C) and HEL (B & D) cells were treated with OEOA (1 µM) for 6 days. Cell viability was measured by trypan blue exclusion as described in Materials and Methods. Data are mean ± SEM of three independent experiments (* <i>p</i><0.05).</p

OEOA was retained for a longer period in mouse blood plasma than OA.

<p>MS-MS product ion mass spectra of OEOA (A) and OA (B). (C) K562 cells were treated with OA or OEOA (1 µM) for 6 h. Culture media and cell lysates were collected at indicated time points for HPLC-MS/MS analysis. Data was represented as mean ± SEM in cell lysate compared to total exposure, n = 2 (* <i>p</i><0.05). (D) Concentrations of OA and OEOA in mouse plasma after intraperitoneal injection. Blood was collected from mice at different time points after single administration of OA and OEOA. Data was represented as mean ± SEM, n = 2 animals per time point (* <i>p</i><0.05).</p

OEOA attenuated phosphorylation of Rb protein in K562 and Jurket cells.

<p>(A) K562 and Jurket cells were treated with OEOA (0.1–10 µM) for 2 days, and the cell lysates were subjected to Western blot analysis for p-Rb and Rb. Actin served as an equal loading control. Histograms in (B) show the relative expression of p-Rb (normalized to actin) as compared to the vehicle-treated cells. Results were representative blots from three separate experiments, (* <i>p</i><0.05).</p

OEOA promoted erythroid differentiation in K562 cells.

<p>K562 cells were treated with OEOA (0.1–10 µM) for 2 days. Total RNA was reverse transcribed and subjected to real time-PCR analysis with primers specific to <i>γ-globin</i> (A) and <i>cd41b</i> (B), respectively. <i>hprt1</i> served as an internal housekeeping gene control. Data were expressed as fold change to the control cells as mean ± SEM of three independent experiments (* <i>p</i><0.05). (C) K562 cells were treated with OEOA (0.1–10 µM) for 2 days. Western blot analysis of Bcr-Abl and Erk1/2 was performed. Actin served as an equal loading control. Histograms on the right show the relative expression of various proteins (normalized to actin) as compared to the control cells. Results were representative blots from three separate experiments, (* <i>p</i><0.05).</p